These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 25065173)

  • 1. [Hyperlipidemia. New treatment option with Evolocumab].
    Ecker-Schlipf B
    Med Monatsschr Pharm; 2014 Jul; 37(7):271-2. PubMed ID: 25065173
    [No Abstract]   [Full Text] [Related]  

  • 2. Specialty Pharmaceuticals for Hyperlipidemia--Impact on Insurance Premiums.
    Schulman KA; Balu S; Reed SD
    N Engl J Med; 2015 Oct; 373(17):1591-3. PubMed ID: 26444460
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.
    Stein EA; Giugliano RP; Koren MJ; Raal FJ; Roth EM; Weiss R; Sullivan D; Wasserman SM; Somaratne R; Kim JB; Yang J; Liu T; Albizem M; Scott R; Sabatine MS;
    Eur Heart J; 2014 Sep; 35(33):2249-59. PubMed ID: 24598985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihyperlipidemic therapies targeting PCSK9.
    Weinreich M; Frishman WH
    Cardiol Rev; 2014; 22(3):140-6. PubMed ID: 24407047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Risk of cardiovascular complications cut in half?].
    Einecke D
    MMW Fortschr Med; 2015 Apr; 157(6):26. PubMed ID: 26015190
    [No Abstract]   [Full Text] [Related]  

  • 6. Evolocumab in hyperlipidemia.
    Meyer RJ
    N Engl J Med; 2014 Aug; 371(9):876. PubMed ID: 25162897
    [No Abstract]   [Full Text] [Related]  

  • 7. Evolocumab in hyperlipidemia.
    Tomoda H
    N Engl J Med; 2014 Aug; 371(9):876-7. PubMed ID: 25162898
    [No Abstract]   [Full Text] [Related]  

  • 8. Evolocumab in hyperlipidemia.
    Blom DJ; Wasserman SM; Stein EA
    N Engl J Med; 2014 Aug; 371(9):877-8. PubMed ID: 25162896
    [No Abstract]   [Full Text] [Related]  

  • 9. Update of Clinical Trials of Anti-PCSK9 Antibodies.
    Wu NQ; Li S; Li JJ
    Cardiovasc Drugs Ther; 2015 Apr; 29(2):159-69. PubMed ID: 25916406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolocumab (AMG 145) for primary hypercholesterolemia.
    Langslet G; Emery M; Wasserman SM
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):477-88. PubMed ID: 25824308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody.
    Roth EM; Diller P
    Future Cardiol; 2014 Mar; 10(2):183-99. PubMed ID: 24762246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Therapies in the Treatment of High Cholesterol: An Argument to Return to Goal-Based Lipid Guidelines.
    Shrank WH; Barlow JF; Brennan TA
    JAMA; 2015 Oct; 314(14):1443-4. PubMed ID: 26258765
    [No Abstract]   [Full Text] [Related]  

  • 13. [PCSK9 monoclonal antibody inhibition: current evidence and future perspectives of lipid-lowering therapy according to the available results from the ODYSSEY program].
    Lettino M
    G Ital Cardiol (Rome); 2015 Apr; 16(4):211-6. PubMed ID: 25959756
    [No Abstract]   [Full Text] [Related]  

  • 14. Improving the care of high-risk patients: the potential of PCSK9.
    Stock J
    Atherosclerosis; 2014 Feb; 232(2):420-2. PubMed ID: 24468158
    [No Abstract]   [Full Text] [Related]  

  • 15. PCSK9: is it fluoride for cardiology?
    King SB
    JACC Cardiovasc Interv; 2014 Nov; 7(11):1331-2. PubMed ID: 25459045
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapy and clinical trials.
    Sodhi N; Krasuski RA
    Curr Opin Lipidol; 2013 Jun; 24(3):281-2. PubMed ID: 23652475
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence.
    Cicero AF; Tartagni E; Ertek S
    Expert Opin Biol Ther; 2014 Jun; 14(6):863-8. PubMed ID: 24661068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Winner by points?--LDL cholesterol as a target for therapeutic intervention.
    Tietge UJ
    Curr Opin Lipidol; 2013 Jun; 24(3):277-8. PubMed ID: 23652473
    [No Abstract]   [Full Text] [Related]  

  • 19. [Anti-PCSK9 in coronary artery disease: genetic progress, therapeutic approaches].
    Abifadel M; Ghaleb Y; Elbitar S; El Khoury P; Rabès JP; Varret M; Boileau C
    Rev Prat; 2015 Mar; 65(3):326-7. PubMed ID: 26016189
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Honarpour N; Blom DJ; Hovingh GK; Xu F; Scott R; Wasserman SM; Stein EA;
    Lancet; 2015 Jan; 385(9965):341-50. PubMed ID: 25282520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.